With a viable Covid-19 vaccine seemingly just around the corner, global investors are increasingly switching out of growth plays towards value stocks. Despite signs of optimism in market laggards, UOB KayHian analyst Adrian Loh urges investors to buy into blue chips with strong financials and dividend-paying ability. 

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply